Trevi Therapeutics Stock Drops on $150M Offering Plan

Stock Plummets After Public Offering News

Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares experienced a significant 10% decline in after-hours trading. The drop followed the company's announcement of a proposed underwritten public offering of its common stock.

Details of the Capital Raise

The clinical-stage biopharmaceutical firm plans to offer $150 million of its common stock. All shares are being sold directly by Trevi. The company is developing Haduvio, an investigational therapy for chronic cough conditions. The offering includes a 30-day option for underwriters to purchase an additional $22.5 million in shares.

Market Reaction and Financial Impact

The immediate market reaction was negative, reflecting potential shareholder dilution from the new stock issuance. Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers, with Oppenheimer & Co. as lead manager for the transaction.

Outlook Summary

The offering aims to raise substantial capital for the company's development pipeline. Investors will be closely watching the final pricing of the offering and its impact on the company's valuation and ongoing clinical trials.

FAQ

Q: Why did Trevi Therapeutics' stock price fall?
A: The stock fell after the company announced a plan to sell $150 million in new common stock, which can dilute the ownership stake of existing shareholders.

Q: Who is managing the stock offering?
A: The offering is being managed by a group of investment banks, with Morgan Stanley, Leerink Partners, Cantor, and Stifel as joint book-running managers.

Source: Investing.com